이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

ALK-Abelló 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Peter Halling

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	1.5yrs
CEO 소유권	n/a
경영진 평균 재임 기간	3.5yrs
이사회 평균 재임 기간	4.3yrs

최근 관리 업데이트

Recent updates

CEO

Peter Halling (47 yo)

1.5yrs

테뉴어

Mr. Peter Halling is President & CEO of ALK-Abelló A/S from 2023. Mr. Peter Halling serves as Chief Executive Officer at Fertin Pharma A/S since August 2020. He has an extensive experience from working in...

리더십 팀

이름	위치	테뉴어	보상	소유권
Claus Solje	Executive VP	1.1yrs	DKK 14.86m	데이터 없음
Søren Niegel	Executive VP of Commercial Operations & Member of Management Board	12.2yrs	DKK 6.51m	0.020% DKK 902.0k
Henriette Mersebach	Executive VP Research & Development & Member of Management Board	1.3yrs	DKK 7.18m	데이터 없음
Katja Thalund	Project Director of Global CMC Development & Employee-elected Director	no data	DKK 350.00k	데이터 없음
Lise Maerkedahl	Project Director of Global Research & Employee-elected Director	no data	DKK 270.00k	데이터 없음
Peter Halling	President & CEO	1.5yrs	데이터 없음	데이터 없음
Per Plotnikof	VP of Corporate Communications	no data	데이터 없음	데이터 없음
Hendrik Kees Nolte	Senior Vice President of Research & Development - North America and International Markets	7.3yrs	데이터 없음	데이터 없음
Christian Houghton	Head of Product Supply	5.5yrs	데이터 없음	데이터 없음
Peter Andersen	Senior Vice President of Global Research & Drug Discovery	no data	데이터 없음	데이터 없음

3.5yrs

평균 재임 기간

53yo

평균 연령

경험이 풍부한 관리: 4AJ0 의 관리팀은 경험 ( 3.4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Katja Thalund	Project Director of Global CMC Development & Employee-elected Director	13.5yrs	DKK 350.00k	데이터 없음
Lise Maerkedahl	Project Director of Global Research & Employee-elected Director	1.3yrs	DKK 270.00k	데이터 없음
Jesper Hoiland	Independent Director	1.3yrs	DKK 366.00k	데이터 없음
Lene Skole-Sorensen	Vice Chairman of the Board	10.5yrs	DKK 900.00k	데이터 없음
Anders Hedegaard	Independent Chairman of the Board	4.3yrs	DKK 1.33m	데이터 없음
Lars Holmqvist	Director	9.3yrs	DKK 446.00k	데이터 없음
Gitte Aabo	Independent Director	3.3yrs	DKK 523.00k	데이터 없음
Alan Main	Independent Director	2.3yrs	DKK 450.00k	데이터 없음
Bertil Lindmark	Independent Director	3.3yrs	DKK 500.00k	데이터 없음
Nanna Carlson	Employee Representative Director	5.3yrs	DKK 350.00k	데이터 없음
Johan Smedsrud	Employee Representative Director	5.3yrs	DKK 350.00k	데이터 없음

4.3yrs

평균 재임 기간

61yo

평균 연령

경험이 풍부한 이사회: 4AJ0 의 이사회는 경험(평균 재직 기간 4.3 년)으로 간주됩니다.

ALK-Abelló 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Insider recently sold €1.2m worth of stock

Alk-Abelló A/S Announces Executive Changes

ALK Announces Management Changes

ALK-Abelló A/S Announces Executive Changes

ALK-Abelló A/S, Annual General Meeting, Mar 23, 2023

ALK Announces Resignation of Søren Jelert as CFO, Effective May 31, 2023

Recent updates

ALK Presents Positive Phase 3 Paediatric Trial Data Offering New Hope for Children with Respiratory Allergy

Now 20% undervalued

Alk's European Registration Application for Itulazax for Pneumiatric Indication Accepted for Review

Now 20% undervalued

Investor sentiment improves as stock rises 22%

First quarter 2024 earnings released

ALK-Abelló A/S Updates Revenue Guidance for the Year 2024

Insider recently sold €1.2m worth of stock

Full year 2023 earnings released

Alk-Abelló A/S Provides Revenue Guidance for the Year of 2024

Alk's European Registration Application for House Dust Mite Slit-Tablet in Young Children Accepts for Review

ALK-Abelló A/S Completes First Part of Phase 1 Trial with Peanut Slit-Tablet

ALK-Abelló A/S to Report Q2, 2024 Results on Aug 23, 2024

ALK-Abelló A/S to Report Fiscal Year 2023 Results on Feb 08, 2024

Third quarter 2023 earnings released: EPS: kr.0.50 (vs kr.0.20 in 3Q 2022)

Investor sentiment improves as stock rises 18%

Alk-Abelló A/S Provides Earnings Guidance for the Year 2023

ALK Announces Top-Line Results from A Phase 3 Pneumiatric Clinical Trial of Its Sublingual Allergy Immunotherapy Tablet for the Treatment of Tree-Pollen-Induced Allergy Immunotherapy Tablet

ALK-Abelló A/S Narrows Revenue Guidance for the Full Year 2023

Investor sentiment deteriorates as stock falls 17%

Alk-Abelló A/S Announces Executive Changes

Alk Announces Top-Line Results from A Phase 3 Paediatric Clinical Trial of Its Sublingual Allergy Immunotherapy Tablet for the Treatment of House Dust Mite (HDM) Induced Allergic Rhinitis

ALK-Abelló A/S Provides Earnings Guidance for the Full Year 2023

First quarter 2023 earnings released

Now 26% undervalued after recent price drop

ALK Announces Management Changes

Full year 2022 earnings released

ALK-Abelló A/S Provides Revenue Guidance for the Full Year 2023

U.S. FDA Approves ALK's ODACTRA® (House Dust Mite Allergen Extract) Tablet for Sublingual Use as Immunotherapy for Adolescents

ALK-Abelló A/S Announces Executive Changes

ALK-Abelló A/S, Annual General Meeting, Mar 23, 2023

ALK Announces Resignation of Søren Jelert as CFO, Effective May 31, 2023

Less than half of directors are independent

Third quarter 2022 earnings released

ALK-Abelló A/S Provides Earnings Guidance for the Year 2022

Second quarter 2022 earnings released

ALK-Abelló A/S Provides Earnings Guidance for the Year 2022

ALK Begins Clinical Trial Of Its Slit-tablet For The Treatment Of Peanut Allergy

Now 24% undervalued after recent price drop

Alk-Abelló A/S Announces Executive Changes

Now 21% undervalued

First quarter 2022 earnings released

ALK-Abelló A/S Provides Earnings Guidance for the Year 2022

Less than half of directors are independent

ALK Expects to Submit Registration Application in China for its House Dust Mite (HDM) Sublingual Allergy Immunotherapy (Slit) Tablet Already in 2022

Now 20% undervalued after recent price drop

Now 20% undervalued after recent price drop

Full year 2021 earnings: Revenues in line with analyst expectations

ALK-Abelló A/S Provides Earnings Guidance for the Fiscal Year 2022

ALK-Abelló A/S Provides Earnings Guidance for the Fiscal Year 2022

ALK-Abelló A/S Announces Results from the REACT Study

Third quarter 2021 earnings released

Second quarter 2021 earnings released

ALK-Abelló A/S Revises Earnings Guidance for the Full-Year of 2021

ALK-Abelló A/S (CPSE:ALK B) acquired OTIPRIO from Otonomy, Inc. (NasdaqGS:OTIC).

First quarter 2021 earnings released

ALK Provides Earnings Guidance for the Year 2021

Revenue misses expectations

New 90-day high: €364

Full year 2020 earnings released

New 90-day high: €344

ALK-Abelló A/S to Report Q2, 2021 Results on Aug 11, 2021

New 90-day high: €309

Revenue misses expectations

New 90-day high: €306

ALK Announces ITULATEK Sublingual Allergy Immunotherapy (Slit)-Tablet

ALK-AbellÃ³ A/S to Report Q3, 2010 Results on 11/16/2010

Earnings released

New 90-day high - €257